Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B.

Oncotarget - 14 Feb 2017

Li Min-Ran, Zheng Huan-Wei, Lu Jian-Hua, Ma Shun-Mao, Ye Li-Hong, Liu Zhi-Quan, Zhang Hai-Cong, Liu Yun-Yan, Lv Ying, Huang Yan, Dai Er-Hei, Sun Dian-Xing

Abstract excerpt

BACKGROUND: Previous studies have revealed that hepatitis B core antibody (anti-HBc) levels vary throughout the different phases of treatment-naïve chronic hepatitis B (CHB) patients and can be used as a predictor of treatment response in both interferon-α and nucleoside analogue therapies. However, few data have been published regarding the relationship between quantitative anti-HBc (qAnti-HBc) levels and liver...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Antibodies
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Host-Pathogen Interactions

Share to Liver Cirrhosis

Share to Logistic Models

Share to ROC Curve

Source

Open in PubMed Open full text

Identifiers

PMID: 28052021
DOI: 10.18632/oncotarget.14323
PMCID: PMC5355246

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B.PMID 28052021Read ↗

Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-naïve chronic hepatitis B patients.Semantic proximity Read ↗

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.Semantic proximity Read ↗

How Effective Are Serum Scoring Systems in Predicting Liver Fibrosis Caused by Chronic Hepatitis B? Serum Scoring Systems and Liver FibrosisSemantic proximity Read ↗

Development of hepatocellular carcinoma in chronic hepatitis B patients with advanced fibrosis is independent of viral genotype.Semantic proximity Read ↗

Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection.Semantic proximity Read ↗

Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients.Semantic proximity Read ↗

Development of a fibrosis index including hepatitis B virus basal core promoter A1762T mutation for pretherapeutic evaluation.Semantic proximity Read ↗

The relationship between serum hepatitis B core-related antigen and hepatitis B virus DNA in treatment-naïve patients with hepatitis B cirrhosis: A cross-sectional studySemantic proximity Read ↗

King's Score: an accurate marker of cirrhosis in chronic hepatitis C.Semantic proximity Read ↗

Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America.Semantic proximity Read ↗

Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers.Semantic proximity Read ↗

Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.